Overview Dividends

(CDTX) Cidara Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1717572069

Antifungal, Antiviral, Oncology, Immunotherapy, Conjugate

Biotechnology
Market Cap in USD: 6,946m
IPO / Inception: 2015-04-15
Return 12m vs S&P 500: 602%

EPS (Earnings per Share)

EPS (Earnings per Share) of CDTX over the last years for every Quarter: "2020-12": -0.49, "2021-03": -0.39, "2021-06": 0.18, "2021-09": -0.37, "2021-12": -0.26, "2022-03": -0.27, "2022-06": -0.19, "2022-09": 0.17, "2022-12": -0.19, "2023-03": 0.03, "2023-06": -0.14, "2023-09": -0.09, "2023-12": -0.04, "2024-03": -2.28, "2024-06": -19.99, "2024-09": -2.45, "2024-12": -5.38, "2025-03": -1.66, "2025-06": -1.65, "2025-09": -3.1,
EPS CAGR: -4.05%
EPS Trend: -67.1%
Last SUE: -0.05
Qual. Beats: 0

Revenue

Revenue of CDTX over the last years for every Quarter: 2020-12: 3.729, 2021-03: 2.408, 2021-06: 32.863, 2021-09: 7.076, 2021-12: 7.225, 2022-03: 7.109, 2022-06: 6.216, 2022-09: 40.744, 2022-12: 10.219, 2023-03: 26.107, 2023-06: 5.09, 2023-09: 9.217, 2023-12: 17.583, 2024-03: 0.973, 2024-06: 0.302, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0,
Rev. CAGR: -50.32%
Rev. Trend: -80.6%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 72.5%
Value at Risk 5%th 82.6%
Relative Tail Risk -30.79%
Reward TTM
Sharpe Ratio 1.79
Alpha 692.90
CAGR/Max DD 1.70
Character TTM
Hurst Exponent 0.502
Beta 0.890
Beta Downside 1.785
Drawdowns 3y
Max DD 74.32%
Mean DD 42.80%
Median DD 47.47%

Description: CDTX Cidara Therapeutics December 01, 2025

Cidara Therapeutics (NASDAQ: CDTX) is a San Diego-based biotech that develops targeted therapies for serious diseases, most notably antifungal and antiviral agents. Its lead product, rezafungin acetate, is a next-generation echinocandin designed to treat and prevent invasive fungal infections such as candidemia, which carry mortality rates above 40 %.

The company’s pipeline also includes the Cloudbreak platform, which creates drug-Fc conjugates. Through this platform, CDTX is advancing CD388, a broad-spectrum antiviral intended for universal seasonal and pandemic influenza protection; CD388 is currently in Phase 1 and Phase 2a trials. Rezafungin has earned FDA Fast-Track designation (2022) and is slated for a Phase 3 pivotal study in 2025.

As of Q2 2024, Cidara reported roughly $120 million of cash and marketable securities, giving it an estimated 12-month runway at current burn rates. The global antifungal market is projected to reach $6 billion by 2028, growing at ~7 % CAGR, while biotech R&D spending is expanding ~8 % YoY, supporting strong demand for novel agents. For a deeper quantitative comparison of CDTX’s valuation metrics, you might explore ValueRay’s analyst tools.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-184.7m TTM) > 0 and > 6% of Revenue (6% = 76.5k TTM)
FCFTA -0.26 (>2.0%) and ΔFCFTA 73.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 27.2k% (prev 596.2%; Δ 26.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.26 (>3.0%) and CFO -132.9m > Net Income -184.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 4.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (15.5m) change vs 12m ago 138.1% (target <= -2.0% for YES)
Gross Margin -9966 % (prev 61.96%; Δ -10.0kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.37% (prev 11.62%; Δ -11.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -36.08 (EBITDA TTM -189.9m / Interest Expense TTM -5.27m) >= 6 (WARN >= 3)

Altman Z'' -12.15

(A) 0.67 = (Total Current Assets 442.8m - Total Current Liabilities 95.8m) / Total Assets 518.6m
(B) -1.43 = Retained Earnings (Balance) -743.7m / Total Assets 518.6m
warn (B) unusual magnitude: -1.43 — check mapping/units
(C) -0.56 = EBIT TTM -190.1m / Avg Total Assets 340.5m
(D) -7.73 = Book Value of Equity -743.8m / Total Liabilities 96.3m
Total Rating: -12.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 23.49

1. Piotroski 0.50pt
2. FCF Yield -2.00%
3. FCF Margin data missing
4. Debt/Equity 0.00
5. Debt/Ebitda 1.54
6. ROIC - WACC (= -71.19)%
7. RoE -60.15%
8. Rev. Trend -80.57%
9. EPS Trend -67.14%

What is the price of CDTX shares?

As of January 07, 2026, the stock is trading at USD 221.38 with a total of 2,691,011 shares traded.
Over the past week, the price has changed by +0.26%, over one month by +0.60%, over three months by +129.53% and over the past year by +725.74%.

Is CDTX a buy, sell or hold?

Cidara Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy CDTX.
  • Strong Buy: 2
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CDTX price?

Issuer Target Up/Down from current
Wallstreet Target Price 221.5 0.1%
Analysts Target Price 221.5 0.1%
ValueRay Target Price 239.1 8%

CDTX Fundamental Data Overview January 03, 2026

Market Cap USD = 6.95b (6.95b USD * 1.0 USD.USD)
P/E Forward = 5.7504
P/S = 4540.699
P/B = 16.445
Beta = 1.464
Revenue TTM = 1.27m USD
EBIT TTM = -190.1m USD
EBITDA TTM = -189.9m USD
Long Term Debt = 1.98m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.56m USD (from shortTermDebt, last quarter)
Debt = 1.98m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -291.7m USD (from netDebt column, last quarter)
Enterprise Value = 6.65b USD (6.95b + Debt 1.98m - CCE 293.7m)
Interest Coverage Ratio = -36.08 (Ebit TTM -190.1m / Interest Expense TTM -5.27m)
FCF Yield = -2.00% (FCF TTM -132.9m / Enterprise Value 6.65b)
FCF Margin = -10.4k% (FCF TTM -132.9m / Revenue TTM 1.27m)
Net Margin = -14.5k% (Net Income TTM -184.7m / Revenue TTM 1.27m)
Gross Margin = -9966 % ((Revenue TTM 1.27m - Cost of Revenue TTM 128.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 12.83 (Enterprise Value 6.65b / Total Assets 518.6m)
Interest Expense / Debt = 31.40% (Interest Expense 623.0k / Debt 1.98m)
Taxrate = -0.0% (0.0 / -170.3m)
NOPAT = -190.1m (EBIT -190.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 4.62 (Total Current Assets 442.8m / Total Current Liabilities 95.8m)
Debt / Equity = 0.00 (Debt 1.98m / totalStockholderEquity, last quarter 422.4m)
Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -291.7m / EBITDA -189.9m)
Debt / FCF = 2.19 (negative FCF - burning cash) (Net Debt -291.7m / FCF TTM -132.9m)
Total Stockholder Equity = 307.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.62% (Net Income -184.7m / Total Assets 518.6m)
RoE = -60.15% (Net Income TTM -184.7m / Total Stockholder Equity 307.1m)
RoCE = -61.49% (EBIT -190.1m / Capital Employed (Equity 307.1m + L.T.Debt 1.98m))
RoIC = -61.88% (negative operating profit) (NOPAT -190.1m / Invested Capital 307.1m)
WACC = 9.31% (E(6.95b)/V(6.95b) * Re(9.30%) + D(1.98m)/V(6.95b) * Rd(31.40%) * (1-Tc(-0.0)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 85.26%
Fair Price DCF = unknown (Cash Flow -132.9m)
EPS Correlation: -67.14 | EPS CAGR: -4.05% | SUE: -0.05 | # QB: 0
Revenue Correlation: -80.57 | Revenue CAGR: -50.32% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.64 | Chg30d=-0.250 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-6.29 | Chg30d=+1.817 | Revisions Net=+2 | Growth EPS=+22.1% | Growth Revenue=+0.0%

Additional Sources for CDTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle